Market Update (NYSE:BMY): REPEAT/ Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1

[Business Wire] – Bristol-Myers Squibb Company announced on Saturday that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy (ipilimuma Read more on this. Bristol-Myers Squibb Company (BMY) , with a current value of $105.97B, began trading this morning at $64.23. During today’s session, BMY traded between $63.51 to $64.40 with a one year range of $51.82 to $70.87. Bristol-Myers Squibb (BMY) shares are currently priced at 33.72x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -2.14x earnings multiple for the same period. And for income investors, the company pays shareholders $1.52 per share annually in dividends, yielding 2.36%. According to a consensus of 19 analysts, the earnings estimate of $0.28 per share would be $0.18 worse than the year-ago quarter and a $0.03 sequential increase. The full-year EPS estimate is $1.91, which would be a $0.06 better than last year. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $4.14 Billion. If realized, that would be a 2.82% decrease over the year-ago quarter. Recently, Berenberg upgraded BMY from Hold to Buy (Jan 22, 2016). Previously, Piper Jaffray upgraded BMY from Underweight to Neutral. With the above information in mind, readers should note that the average price target is $74.10, which is 15.37% above where the stock opened this morning. See more in (NYSE:BMY) Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – SomaLogic Completes Agreement With Bristol-Myers Squibb for Expanded Access to SOMAmer(R) Reagents Company Update (NYSE:BMY): Bristol-Myers Squibb to Present New Data for Opdivo (nivolumab) in Advanced Melanoma, as Monotherapy and in Combination with Yervoy (ipilimumab), at the Society for Melanoma Research 2015 International Congress Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product